Provided by Tiger Trade Technology Pte. Ltd.

Quantum Biopharma Ltd.

3.44
+0.01500.44%
Post-market: 3.440.00000.00%19:31 EDT
Volume:79.31K
Turnover:270.33K
Market Cap:27.82M
PE:-0.64
High:3.47
Open:3.38
Low:3.32
Close:3.43
52wk High:19.00
52wk Low:2.07
Shares:8.09M
Float Shares:7.65M
Volume Ratio:0.61
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.3537
EPS(LYR):-7.9660
ROE:-621.46%
ROA:-51.84%
PB:3.50
PE(LYR):-0.43

Loading ...

Broadcom, Quantinuum, Strategy, Tesla, and More Stocks That Explain Today's Market -- Barrons.com

Dow Jones
·
Jun 06

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

TIPRANKS
·
Jun 05

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast

TIPRANKS
·
Jun 03

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

GlobeNewswire
·
Jun 02

Quantum BioPharma Provides Corporate Update

GlobeNewswire
·
Jun 02

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 PM

Reuters
·
Jun 02

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study

TIPRANKS
·
May 19

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

GlobeNewswire
·
May 18

Press Release: Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Dow Jones
·
May 07

Quantum BioPharma Provides Corporate Update

GlobeNewswire
·
Apr 28

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

GlobeNewswire
·
Apr 22

Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

GlobeNewswire
·
Apr 02

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

GlobeNewswire
·
Apr 01

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:50 AM

Reuters
·
Mar 30

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

GlobeNewswire
·
Mar 30